2026-01-10 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical (ISRG) based on the data provided.

**1) Return Rate Comparison and Alpha/Beta Analysis:**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **Return Rate:** ISRG's cumulative return is 85.88% compared to VOO's (S&P 500) 92.74%.
*   **Divergence:** ISRG is currently lagging VOO, with a divergence of -12.4%. Its relative divergence of 29.2 indicates that this divergence is relatively small compared to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2016-2018  | 49.0%  | 29.0% | 45.0%  | 1.2  | 57.3   |
| 2017-2019  | 40.0%  | 29.0% | 23.0%  | 1.4  | 70.8   |
| 2018-2020  | -8.0%  | 29.0% | -29.0% | 1.2  | 98.0   |
| 2019-2021  | 26.0%  | 21.1% | -17.0% | 1.2  | 129.1  |
| 2020-2022  | -18.0% | 48.9% | -16.0% | 1.2  | 95.3   |
| 2021-2023  | -12.0% | 48.9% | -13.0% | 1.4  | 121.2  |
| 2022-2024  | 35.0%  | 38.0% | 16.0%  | 1.3  | 187.5  |
| 2023-2025  | 60.0%  | 28.0% | -2.0%  | 1.2  | 203.4  |

*   **CAGR (Compound Annual Growth Rate):** Shows the average annual growth over the period.  Notice the significant volatility, with periods of very high growth (2016-2018, 2023-2025) and negative growth (2018-2020, 2020-2022, 2021-2023).
*   **MDD (Maximum Drawdown):** Indicates the largest peak-to-trough decline during the period. ISRG experienced some large drawdowns, particularly in 2020-2022 and 2021-2023.
*   **Alpha:** Measures the excess return compared to the benchmark (S&P 500) after accounting for risk (Beta). A negative alpha indicates underperformance relative to the benchmark, while a positive alpha indicates outperformance.  ISRG has shown varying Alpha.
*   **Beta:** Measures the stock's volatility relative to the market. A Beta of around 1.2-1.4 indicates that ISRG is more volatile than the S&P 500.
*   **Cap(B):** Market capitalization in billions. Shows substantial growth over time, indicating increasing investor confidence and company value.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 585.08
*   **Last Market Data:** Price: 586.24, Previous Close: 585.08, Change: 0.2
*   **Moving Averages:**
    *   5-day SMA: 579.71
    *   20-day SMA: 568.8
    *   60-day SMA: 549.82

*   **Analysis:** The stock is trading slightly above its previous close, with a positive change.  The 5-day SMA is above the 20-day SMA, and both are above the 60-day SMA, suggesting an upward trend in the short to medium term. The price is currently fluctuating slightly as today's last trade price (586.24) is slightly above today's close price (585.08).

**3) RSI, PPO, and Expected Return Analysis:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment) - Suggests a moderate level of risk.
*   **RSI:** 67.47 - Approaching overbought territory (above 70).
*   **PPO:** 0.17 - Positive, indicating a possible upward trend in momentum.
*   **Hybrid Signal:** Buy 90% of cash (2 shares) - Suggests a bullish sentiment based on the algorithm.
*   **Recent Relative Divergence Change:** -2.3 (Negative) - Indicates a short-term decline relative to the S&P 500.
*   **Expected Return:** 4.3% - Indicates a positive expected return compared to the S&P 500 over a long-term investment horizon.

**4) Recent News & Significant Events:**

*   **Positive Analyst Sentiment:** Multiple news articles highlight raised price targets from Truist, RBC Capital, and Bernstein. Bernstein's target is particularly optimistic at $740.
*   **"Buy and Hold" Recommendation:** Seeking Alpha article suggests ISRG is an easy "buy and hold" stock for long-term outperformance.
*   **FDA Approval:** Recent FDA greenlight for a medical robotics application could be a positive catalyst.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 2.06 (~Buy)
*   **Target Price:** Average: $608.26, High: $740.00, Low: $378.00.  The wide range in target prices suggests some disagreement among analysts, but the average is above the current price.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-10-22 | 1.98 | 2.51 B$  |
| 2025-07-23 | 1.84 | 2.44 B$  |
| 2025-04-23 | 1.95 | 2.25 B$  |
| 2024-10-18 | 1.59 | 2.04 B$  |
| 2025-10-22 | 1.59 | 2.04 B$  |

*Note: The last entry is duplicated, but it will be analyzed assuming the latest date is correct.*

*   **EPS (Earnings Per Share):**  Generally trending upwards over the past year, which is a positive sign. From 1.59 (2024-10-18) to 1.98 (2025-10-22).
*   **Revenue:** Increasing over the past year, indicating healthy sales growth. From 2.04B$ (2024-10-18) to 2.51B$ (2025-10-22).

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $2.51B    | 66.36%        |
| 2025-06-30 | $2.44B    | 66.31%        |
| 2025-03-31 | $2.25B    | 64.69%        |
| 2024-12-31 | $2.41B    | 68.04%        |
| 2024-09-30 | $2.04B    | 67.41%        |

*   **Revenue:** Confirms the upward trend observed in the earnings data.
*   **Profit Margin:**  Remains consistently high, demonstrating strong profitability and efficient operations. There is a slight decrease in margin between 2024-12-31 and 2025-03-31, but it recovers somewhat in the following quarters.

**Capital and Profitability:**

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-09-30 | $16.93B   | 4.16%  |
| 2025-06-30 | $17.85B   | 3.69%  |
| 2025-03-31 | $17.11B   | 4.08%  |
| 2024-12-31 | $16.43B   | 4.17%  |
| 2024-09-30 | $15.58B   | 3.63%  |

*   **Equity:** Fluctuating, showing the company's net worth.
*   **ROE (Return on Equity):**  Indicates how efficiently the company is using shareholder investments to generate profits. The ROE is fluctuating somewhat.

**7) Comprehensive Analysis:**

*   **Overall:** ISRG is a fundamentally strong company with a dominant position in the robotic surgery market. Recent news and analyst opinions are generally positive, with multiple price target increases.
*   **Return:** While ISRG has underperformed the S&P 500 over the past year, its long-term growth potential remains significant.
*   **Financials:** The company demonstrates strong revenue growth and high-profit margins.
*   **Technicals:** The current technical indicators suggest an upward trend in the short to medium term. However, the RSI is approaching overbought levels, which could indicate a potential pullback.
*   **Risk:** The stock is more volatile than the S&P 500, as indicated by its beta. The Market Risk Indicator (MRI) suggests a medium level of risk.
*   **Recommendations:**
    *   **Positive Signals:** Strong fundamentals, positive analyst outlook, and recent upward price movement.
    *   **Cautions:** Higher volatility, RSI approaching overbought levels, and some divergence from the S&P 500.
    *   **Overall:** The data suggests that ISRG is a potentially attractive investment for the long term, but investors should be aware of the inherent risks associated with growth stocks and the possibility of short-term price fluctuations. The hybrid signal gives a "buy" rating.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.